National Committee on Vital and Health Statistics: Meeting, 52324-52325 [2015-21328]

Download as PDF 52324 Federal Register / Vol. 80, No. 167 / Friday, August 28, 2015 / Notices Dated: August 14, 2015. James Macrae, Acting Administrator, Health Resources and Services Administration. Approved: August 17, 2015. Sylvia M. Burwell, Secretary. [FR Doc. 2015–21246 Filed 8–27–15; 8:45 am] BILLING CODE 4165–15–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of the Secretary Findings of Research Misconduct Office of the Secretary, HHS. Notice. AGENCY: ACTION: Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case: Brandi Blaylock, Wake Forest School of Medicine: Based on an investigation conducted by Wake Forest School of Medicine (WFSOM) and additional analysis conducted by ORI, ORI found that Ms. Brandi Blaylock, former Graduate Student, WFSOM, engaged in research misconduct in research supported by National Institute of Drug Abuse (NIDA), National Institutes of Health (NIH), grant R01 DA012460 and Ruth L. Kirschstein National Research Service Award (NRSA) K31 DA033106. ORI found that Respondent engaged in research misconduct by falsifying and/or fabricating data reported in two poster presentations, several laboratory meetings, and progress reports associated with NIDA, NIH, grant R01 DA012460. Specifically, ORI found that the Respondent knowingly presented falsified and/or fabricated data indicating that twelve non-human primates (either rhesus or cynomolgus monkeys) responded to anti-abuse nicotinic acetylcholine and/or dopamine receptor selective compounds in self-selectivity assays for cocaine, methamphetamines, or nicotine when the compounds were never given to the monkeys per protocol. Respondent has not applied for or engaged in U.S. Public Health Service (PHS)-supported research within the last three (3) years and has stated that she has no intention of engaging in PHSsupported research in the future. Ms. Blaylock has entered into a Voluntary Settlement Agreement and has voluntarily agreed: (1) That if within three (3) years from the effective date of the Agreement, Respondent receives or applies for PHS Lhorne on DSK5TPTVN1PROD with NOTICES SUMMARY: VerDate Sep<11>2014 14:19 Aug 27, 2015 Jkt 235001 support, Respondent agreed to have her research supervised for a period of three (3) years beginning on the date of her employment in a position in which she receives or applies for PHS support and to notify her employer(s)/institution(s) of the terms of this supervision; Respondent agreed that prior to the submission of an application for PHS support for a research project on which her participation is proposed and prior to her participation in any capacity on PHS-supported research, Respondent shall ensure that a plan for supervision of her duties is submitted to ORI for approval; the supervision plan must be designed to ensure the scientific integrity of her research contribution; Respondent agreed that she shall not participate in any PHS-supported research until such a supervision plan is submitted to and approved by ORI; Respondent agreed to maintain responsibility for compliance with the agreed upon supervision plan; (2) that if within three (3) years from the effective date of the Agreement, Respondent receives or applies for PHS support, Respondent agreed that for a period of three (3) years beginning on the data of her employment in a position in which she receives or applies for PHS support, any institution employing her shall submit in conjunction with each application for PHS funds, or report, manuscript, or abstract involving PHS-supported research in which Respondent is involved, a certification to ORI that the data provided by Respondent are based on actual experiments or are otherwise legitimately derived, and that the data, procedures, and methodology are accurately reported in the application, report, manuscript, or abstract; and (3) to exclude herself voluntarily from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant for a period of three (3) years, beginning on August 4, 2015. FOR FURTHER INFORMATION CONTACT: Acting Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453– 8200. Donald Wright, Acting Director, Office of Research Integrity. [FR Doc. 2015–21354 Filed 8–27–15; 8:45 am] BILLING CODE 4150–31–P PO 00000 Frm 00080 Fmt 4703 Sfmt 4703 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Committee on Vital and Health Statistics: Meeting Pursuant to the Federal Advisory Committee Act, the Department of Health and Human Services (HHS) announces the following advisory committee meeting. Name: National Committee on Vital and Health Statistics (NCVHS); Full Committee Meeting. Time and Date: September 16, 2015; 9:00 a.m.–5:30 p.m. EST. September 17, 2015; 8:30 a.m.–12:00 p.m. EST. Place: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics, 3311 Toledo Road, Auditorium A and B, Hyattsville, Maryland 20782, (301) 458–4524. Status: Open. Purpose: The purpose of this meeting is to review NCVHS Status of Activities, outline remaining objectives and deliverables for 2015 and engage in strategic planning for the next phase of Committee work. The Committee will review and coordinate ongoing efforts being carried out by Subcommittees and implementing its ACA-designated Review Committee. Additional topics will include one action item for approval: a letter on § 1179 of the HIPAA statute; and a presentation on the IOM Report ‘‘Vital Signs: Core Metrics for Health and Health Care Progress.’’ The Working Group on HHS Data Access and Use will continue strategic discussions on Building a Framework for Guiding Principles for Data Access and Use. The times shown above are for the full Committee meeting. Subcommittee issues will be included as part of the Full Committee schedule. Contact Person for More Information: Substantive program information may be obtained from Rebecca Hines, Acting Executive Secretary, NCVHS, National Center for Health Statistics, Centers for Disease Control and Prevention, 3311 Toledo Road, Room 6316, Hyattsville, Maryland 20782, telephone (301) 458– 4715. Summaries of meetings and a roster of committee members are available on the NCVHS home page of the HHS Web site: https:// www.ncvhs.hhs.gov/, where further information including an agenda will be posted when available. Should you require reasonable accommodation, please contact the CDC Office of Equal Employment E:\FR\FM\28AUN1.SGM 28AUN1 Federal Register / Vol. 80, No. 167 / Friday, August 28, 2015 / Notices Opportunity on (301) 458–4EEO (4336) as soon as possible. Dated: August 24, 2015. James Scanlon, Deputy Assistant Secretary for Planning and Evaluation (Science and Data Policy), Office of the Assistant Secretary for Planning and Evaluation. [FR Doc. 2015–21328 Filed 8–27–15; 8:45 am] BILLING CODE 4151–05–P Bethesda, MD 20899823, (240) 669–5062, wurstera@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) Dated: August 25, 2015. David Clary, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2015–21378 Filed 8–27–15; 8:45 am] DEPARTMENT OF HEALTH AND HUMAN SERVICES BILLING CODE 4140–01–P National Institutes of Health DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings National Institutes of Health Lhorne on DSK5TPTVN1PROD with NOTICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID Clinical Trial Implementation (R01). Date: September 22, 2015. Time: 12:00 p.m. to 2:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Room 3G33, 5601 Fishers Lane, Rockville, MD 20892, (Telephone Conference Call). Contact Person: Andrea L Wurster, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, Room 3G33B, National Institutes of Health, NIAID, 5601 Fishers Lane, MSC 9823, Bethesda, MD 20899823, (240) 669–5062, wurstera@mail.nih.gov. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID Clinical Trial Planning Grant (R34). Date: September 25, 2015. Time: 10:00 a.m. to 12:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Room 3G33, 5601 Fishers Lane, Rockville, MD 20892, (Telephone Conference Call). Contact Person: Andrea L Wurster, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, Room 3G33B, National Institutes of Health, NIAID, 5601 Fishers Lane, MSC 9823, VerDate Sep<11>2014 14:19 Aug 27, 2015 Jkt 235001 Proposed Collection; 60-day Comment Request: A Multi-Center International Hospital-Based Case-Control Study of Lymphoma in Asia (AsiaLymph) (NCI) In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the National Cancer Institute, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. Written comments and/or suggestions from the public and affected agencies are invited to address one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) The accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) The quality, utility, and clarity of the information to be collected; and (4) Minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology. To Submit Comments and for Further Information: To obtain a copy of the data collection plans and instruments, submit comments in writing, or request more information on the proposed project, contact: Nathaniel Rothman, Senior Investigator, Division of Cancer Epidemiology and Genetics, 9609 Medical Center Drive, MSC 9776, Room 6E134, Bethesda, Maryland 20892 or call non-toll-free number (240) 276– 7169 or Email your request, including SUMMARY: PO 00000 Frm 00081 Fmt 4703 Sfmt 4703 52325 your address to: rothmann@ mail.nih.gov. Formal requests for additional plans and instruments must be requested in writing. Comment Due Date: Comments regarding this information collection are best assured of having their full effect if received within 60 days of the date of this publication. Proposed Collection: A Multi-Center International Hospital-Based CaseControl Study of Lymphoma in Asia (AsiaLymph) (NCI), 0925–0654, Expiration Date 10/31/2015–REVISION, National Institutes of Health (NIH). Need and Use of Information Collection: Incidence rates of certain lymphomas have increased in the United States and in many other parts of the world. The contribution of environmental, occupational, and genetic factors to the cause of lymphoma and leukemia has generated a series of novel findings from epidemiological studies conducted in the United States that have attempted to explain this increase. However, none of the chemical associations have been conclusively established and the identification of the key, functional alleles in gene regions associated with risk of lymphoma requires further elucidation. Further, the ability to follow-up, confirm, and extend these observations in the United States is limited by the low prevalence and limited range of several important chemical and viral exposures and the high to complete linkage disequilibrium among key candidate genetic loci in Western populations. To optimize the ability to build on and clarify these findings, it is necessary to investigate populations that differ from those in the West in both exposure patterns and underlying genetic structure. A multidisciplinary case-control study of lymphoma in Asia, where lymphoma rates have also risen, provides an opportunity to replicate and extend recent and novel observations made in studies in the West in a population that is distinctly different with regard to patterns of key risk factors, including range of exposures, prevalence of exposures, correlations between exposures, and variation in gene regions of particular interest. It will also improve the ability to understand the causes of certain types of rare lymphoma tumors in the United States that occur at much higher rates in Asia. As such, AsiaLymph will confirm and extend previous findings and yield novel insights into the causes of lymphoma and leukemia in both Asia and in the United States. The major postulated risk factors for evaluation in this study are chemical exposures (i.e., E:\FR\FM\28AUN1.SGM 28AUN1

Agencies

DEPARTMENT OF HEALTH AND HUMAN SERVICES

[Federal Register Volume 80, Number 167 (Friday, August 28, 2015)]
[Notices]
[Pages 52324-52325]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-21328]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES


National Committee on Vital and Health Statistics: Meeting

    Pursuant to the Federal Advisory Committee Act, the Department of 
Health and Human Services (HHS) announces the following advisory 
committee meeting.
    Name: National Committee on Vital and Health Statistics (NCVHS); 
Full Committee Meeting.
    Time and Date:

September 16, 2015; 9:00 a.m.-5:30 p.m. EST.
September 17, 2015; 8:30 a.m.-12:00 p.m. EST.

    Place: U.S. Department of Health and Human Services, Centers for 
Disease Control and Prevention, National Center for Health Statistics, 
3311 Toledo Road, Auditorium A and B, Hyattsville, Maryland 20782, 
(301) 458-4524.
    Status: Open.
    Purpose: The purpose of this meeting is to review NCVHS Status of 
Activities, outline remaining objectives and deliverables for 2015 and 
engage in strategic planning for the next phase of Committee work. The 
Committee will review and coordinate ongoing efforts being carried out 
by Subcommittees and implementing its ACA-designated Review Committee. 
Additional topics will include one action item for approval: a letter 
on Sec.  1179 of the HIPAA statute; and a presentation on the IOM 
Report ``Vital Signs: Core Metrics for Health and Health Care 
Progress.'' The Working Group on HHS Data Access and Use will continue 
strategic discussions on Building a Framework for Guiding Principles 
for Data Access and Use.
    The times shown above are for the full Committee meeting. 
Subcommittee issues will be included as part of the Full Committee 
schedule.
    Contact Person for More Information: Substantive program 
information may be obtained from Rebecca Hines, Acting Executive 
Secretary, NCVHS, National Center for Health Statistics, Centers for 
Disease Control and Prevention, 3311 Toledo Road, Room 6316, 
Hyattsville, Maryland 20782, telephone (301) 458-4715. Summaries of 
meetings and a roster of committee members are available on the NCVHS 
home page of the HHS Web site: https://www.ncvhs.hhs.gov/, where further 
information including an agenda will be posted when available.
    Should you require reasonable accommodation, please contact the CDC 
Office of Equal Employment

[[Page 52325]]

Opportunity on (301) 458-4EEO (4336) as soon as possible.

    Dated: August 24, 2015.
James Scanlon,
Deputy Assistant Secretary for Planning and Evaluation (Science and 
Data Policy), Office of the Assistant Secretary for Planning and 
Evaluation.
[FR Doc. 2015-21328 Filed 8-27-15; 8:45 am]
 BILLING CODE 4151-05-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.